In this episode, John Giacona, PhD, PA-C, shares insights from the 2024 AHA Hypertension Scientific Sessions, focusing on primary aldosteronism and renal denervation.

Calabrese discussed factors for rheumatologists to keep in mind, including recent travel and screening for viral infections.

In an interview O’Donoghue talked about emerging RNA therapies for Lp(a) in phase 2 and 3 trials.

A large study shows no women were anemic in the first trimester of pregnancy, but more than 80% of the women were iron deficient by the third trimester.

This approval by the FDA follows positive findings from the pivotal BOREAS and NOTUS trials on adults with uncontrolled COPD.

These new data were announced by Celldex Therapeutics regarding the sustained and deepening efficacy of barzolvolimab treatment of chronic spontaneous urticaria.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

HBV education led by healthcare providers, decentralized testing, and strategies with more framework-driven mechanisms had the greatest impact on testing uptake.

Higher Life’s Essential 8 score was associated with higher CVH scores in US adults.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

Elias discusses the challenges of prosthetic valve evaluation, highlighting the role of sonographers, Doppler imaging, and the importance of ongoing training.

This interview with Alexis features his reaction to the approval of lebrikizumab for eczema and its significance.

A randomized trial suggests gefarnate significantly reduces triglycerides and LDL-C in older adults on statins with residual hypertriglyceridemia.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Younger people and people without European origin were less likely to adhere to urate-lowering therapy.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes.

Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.

Rates of absolute and functional iron deficiency were high among adults in the US, even in those without anemia, heart failure, or chronic kidney disease.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.

Physicians who received pharmaceutical industry payments related to 4 different direct-acting antivirals were more likely to prescribe these medications.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

These new findings were released by Arcutis Biotherapeutics and presented at the European Academy of Dermatology & Venereology Congress.

Leveraging deceased donor kidney transplantation data, study results suggest DCD-V kidney transplantation has similar short- and long-term outcomes versus DCD-III and DBD.